Hai-Long Tang1, Mi-Mi Shu1, Bao-Xia Dong1, Hong-Tao Gu1, Rong Liang1, Qing-Xian Bai1, Lan Yang1, Tao Zhang1, Guang-Xun Gao2, Xie-Qun Chen3. 1. Department of Hematology, Xijing Hospital, Fourth Military Medical University, Hematologic Diseases Center of Chinese People's Liberation Army, Xi'an 710032, Shaanxi Province, China. 2. Department of Hematology, Xijing Hospital, Fourth Military Medical University, Hematologic Diseases Center of Chinese People's Liberation Army, Xi'an 710032, Shaanxi Province, China. E-mail:gaoguangxun@fmmu.edu.cn. 3. Department of Hematology, Xijing Hospital, Fourth Military Medical University, Hematologic Diseases Center of Chinese People's Liberation Army, Xi'an 710032, Shaanxi Province, China. E-mail: xiequnchen@fmmu.edu.cn.
Abstract
OBJECTIVE: To investigate the influence of CD117 expression on response of multiple myeloma patients to chemo-therapy. METHODS: A total of 65 cases of newly diagnosed multiple myeloma in our hospital from 2011 to 2013 were enrolled in this study. Cytogenetic abnormalities and immunophenotype were detected by using fluorescence in situ hybridization and flow cytometry before chemotherapy. The therapeutic efficacy of patients was evaluated after 4 cycles of PAD or TAD regimen. RESULTS: The positive rates of 1q21 amplification, RB1: 13q14 deletion, D13S319: 13q14.3 deletion, IgH: 14q32 rearrangement and p53: 17p13 deletion were 32.2%, 40%, 40%, 20% and 3.1% respectively; the positive rates of CD38, CD138, CD56, CD117, CD20 were respectively 100%, 100%, 60%, 20%, 10.8%; the positive rates of CD19 and CD10 were 4.6% and 4.6% respectively; the positive CD22, CD7, CD5, CD103 did not found in any patients. The therapeutic efficacy of CD117⁻ patients was better than that of CD117⁺ patients (P < 0.05), there was no correlation of the remaining indicators with efficacy; the proportion of CD117⁺ patients with β2-microglobulin ≥ 5.5 mg/L was significantly higher than that of CD117⁻ patients (P < 0.05); the rest of baseline data had no significant difference (P > 0.05). CONCLUSION: CD117 can be used as an indicator for evaluating efficacy of patients with newly diagnosed multiple myeloma.
OBJECTIVE: To investigate the influence of CD117 expression on response of multiple myelomapatients to chemo-therapy. METHODS: A total of 65 cases of newly diagnosed multiple myeloma in our hospital from 2011 to 2013 were enrolled in this study. Cytogenetic abnormalities and immunophenotype were detected by using fluorescence in situ hybridization and flow cytometry before chemotherapy. The therapeutic efficacy of patients was evaluated after 4 cycles of PAD or TAD regimen. RESULTS: The positive rates of 1q21 amplification, RB1: 13q14 deletion, D13S319: 13q14.3 deletion, IgH: 14q32 rearrangement and p53: 17p13 deletion were 32.2%, 40%, 40%, 20% and 3.1% respectively; the positive rates of CD38, CD138, CD56, CD117, CD20 were respectively 100%, 100%, 60%, 20%, 10.8%; the positive rates of CD19 and CD10 were 4.6% and 4.6% respectively; the positive CD22, CD7, CD5, CD103 did not found in any patients. The therapeutic efficacy of CD117⁻ patients was better than that of CD117⁺ patients (P < 0.05), there was no correlation of the remaining indicators with efficacy; the proportion of CD117⁺ patients with β2-microglobulin ≥ 5.5 mg/L was significantly higher than that of CD117⁻ patients (P < 0.05); the rest of baseline data had no significant difference (P > 0.05). CONCLUSION:CD117 can be used as an indicator for evaluating efficacy of patients with newly diagnosed multiple myeloma.
Authors: Mihaiela L Dragoș; Iuliu C Ivanov; Mihaela Mențel; Irina C Văcărean-Trandafir; Adriana Sireteanu; Amalia A Titianu; Angela S Dăscălescu; Alexandru B Stache; Daniela Jitaru; Dragoș L Gorgan Journal: Int J Mol Sci Date: 2022-07-07 Impact factor: 6.208